No Picture
News

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China

LA JOLLA, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the?NASDAQ Global Market?(NASDAQ:MNOV) and the JASDAQ Market of the?Tokyo Stock Exchange?(Code Number: 4875), today announced that it has rec… […]

No Picture
News

AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis

SAN DIEGO, Sept. 30, 2019 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced positive topli… […]

No Picture
News

?We are desperate for new therapies?

Experts discuss AML during the Sanford Burnham Prebys community lecture series?

Bill Veljovich had never been sick in his life. ?Not even joint pain,? shared the 80-year-old retired engineer at our recent Fleet Science Center discussion about acute my… […]

No Picture
News

Illumina and Broad Institute Announce Agreement to Co-Develop Genomic Secondary Analysis Tools

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and the Broad Institute of MIT and Harvard today announced they have entered into a collaboration for the co-development of secondary genomic analysis algorithms and software. Top data scientist… […]

No Picture
News

Ribometrix Announces $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform

DURHAM, N.C.–(BUSINESS WIRE)–Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, today announced $7.8 million in additional funding from existing investors, the Dementia Discove… […]